Cytosorbents Corporation: Difference between revisions
moving |
No edit summary |
||
| Line 42: | Line 42: | ||
[[Category:Companies based in New Jersey]] |
[[Category:Companies based in New Jersey]] |
||
[[Category:Companies listed on NASDAQ]] |
[[Category:Companies listed on NASDAQ]] |
||
[[Category:Medical_devices]] |
|||
[[Category:Life_sciences_industry]] |
|||
[[Category:Medical_equipment_manufacturers]] |
|||
{{US-company-stub}} |
{{US-company-stub}} |
||
Revision as of 17:18, 5 May 2016
| Nasdaq: CTSO | |
| Industrie | Critical care |
| Hauptsitz | Monmouth Junction, New Jersey , USA |
| Produkte | CytoSorb |
Number of employees | 52 |
CytoSorbents is a publicly traded company (NasdaqCM: CTSO) located in Monmouth Junction, New Jersey.[1][2][3] Cytosorbents has created a blood purification technology based on biocompatible, highly porous polymer beads that act like sponges in an attempt to remove harmful substances from the blood.[4][5]
CytoSorb, the Company's first product to market, received its CE mark approval in 2011.[6][7]
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.[8] The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma.[9]
References
- ^ "CTSO: Summary for CYTOSORBENTS COR- Yahoo! Finance". YAHOO Finance. Retrieved 9 April 2014.
- ^ "CTSO stock quote – Cytosorbents Corporation stock price – NASDAQ.com". NASDAQ. Retrieved 9 April 2014.
- ^ "CTSO SEC Filings". YAHOO. Retrieved 9 April 2014.
- ^ Baum, Stephanie. "Blood purification device for ICU patients seeks to control cytokine storm". Med City News. Retrieved 2013-05-24.
- ^ "Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy". The International Journal of Artificial Organs. Retrieved 6 May 2014.
- ^ Crutcher, Patrick. "Closer Look: CytoSorbents' Surprise CE Mark Approval". BioMed Reports. Retrieved 4/1/11.
{{cite web}}: Check date values in:|accessdate=(help) - ^ "With EU Regulatory Approval Gained CytoSorbents Corporation (OTCBB: CTSO) One Step Closer to Goal of FDA Regulatory Approval". OTC Equity. Retrieved 9 April 2014.
- ^ "DARPA Dialysis-Like-Therapeutic Program Awards $3.8M to CytoSorbents". Global BioDefense. Retrieved 9 April 2014.
- ^ "CTSO Awarded Ph II U.S. Army Grant". Zacks. Retrieved 9 April 2014.
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |
 | This New Jersey–related article is a stub. You can help Wikipedia by expanding it. |